Opportunities and Challenges for Generic Drugs in the UK 2007

Date: June 22, 2007
Pages: 160
Price:
US$ 1,390.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O41DB5F9B47EN
Leaflet:

Download PDF Leaflet

Opportunities and Challenges for Generic Drugs in the UK 2007
ISSUES AFFECTING THE UK GENERIC MARKET

When is a generic prescription not a generic prescription?

Despite great emphasis being placed on generic prescribing, a significant number of generic prescriptions are not dispensed as such. For example, in England, generics accounted for 80.1% of written prescriptions and 59.3% of prescriptions dispensed in 2005. This means around 415 million prescriptions were dispensed as generics, and around 145.8 million generically-written prescriptions were dispensed as brands. There are several reasons for this; limited generic availability, availability of a cheaper parallel import brand, or on a few occasions the brand was in fact cheaper than the generic.

Price fixing allegations rumble on

The government, ever watchful of the rising drugs bill has taken action against a number of companies who were accused of price-fixing in the generics sector, although there appears to be no swift conclusion. In 2005, two companies Ranbaxy and Generics (UK) did deals with the Department of Health with regard to its civil action. Neither company has admitted any wrongdoing, but both have pledged to co-operate with the ongoing investigations. Despite this co-operation all the companies identified continue to be part of a criminal case brought by the Serious Fraud Office.

Paediatric SPC/patent extension

In 2005, the European Parliament voted in favour of the Regulation on Paediatric Medicines, which among other things grants an additional six months SPC/patent extension for drugs with additional indications for use in children. This was adopted in 2006 and came into force in January 2007.

Outlook for future growth

While the UK generic market is large by international standards, growth is unlikely to outpace the market as a whole over the next few years. Strong competition among manufacturers exerts a strong downward pressure on prices, as does the continuing government monitoring of the UK generic industry in the wake of its various price-fixing lawsuits.

In addition, the government has proved willing to step in to correct reimbursement prices, where these significantly exceed the market. The April 2005 Drug Tariff had the effect of reducing generic prices, and action has also been taken with regard to the price of specific drugs.

Growth in the market, therefore, is likely to be driven by new products becoming available as generics, and steadily rising consumption. Generics are well accepted by consumers and widely used by doctors.

The report answers key questions such as:
  • What is the estimated value of the UK generic market now and in 2012?
  • What is the current pricing and reimbursement situation for generic drugs and how might it change?
  • The market is set to grow over the next 5 years – what will be the drivers?
  • Which companies have marketing authorisation for amlodipine and how does the generic compare to the brand?
  • Major companies in the UK generics industry are merging – will consolidation mean greater price competition?

COMPANIES ANALYSED IN THE REPORT MARKETING AUTHORISATIONS AND PRICE COMPARISONS FOR LEADING PRODUCTS

Actavis UK Ltd
Arrow Generics Ltd
Bristol Laboratories
Crescent Pharma
Dr Reddy's Laboratories (UK) Ltd
Generics (UK) Ltd
Genus Pharmaceuticals
Goldshield Pharmaceuticals Ltd
Focus Pharmaceuticals
Kent Pharmaceuticals
Perrigo UK Ltd
Pliva Pharma Ltd
Ranbaxy (UK) Ltd
ratiopharm UK
Rosemont Pharmaceuticals
Sandoz
Teva UK
Winthrop Pharmaceuticals
Wockhardt UK Ltd Amisulpride
Ramipril
Glimepiride
Ondansetron
Sumatriptan
Amlodipine
Citalopram
Fluconazole
Gabapentin
Lamotrigine
Meloxicam
Sertraline
Tamsulosin
Terbinafine
FOREWORD

INTRODUCTION

BACKGROUND TO THE MARKET


Geography
Political Overview
Economic Overview
Demographics
  Demographic indicators
The UK Healthcare System
  Organisation
    Primary Care Trusts
  Healthcare expenditure
  Hospital beds
  Medical personnel

THE UK GENERICS MARKET

In Context: the UK Pharmaceutical Market
  Market Structure
  Reimbursement
  Pricing: the PPRS
  Unbranded Generic Pricing
    2005 generics reimbursement scheme
    Generic price reductions for four major drugs
    DOH Holds consultations regarding branded generics in the PPRS
  Regulation of Pharmaceuticals
    Generic regulation
  Intellectual Property
    Supplementary Protection Certificates
  Prescription Medicines Market
    England
Generic Market Size
  Generic Prescribing
    Scotland
    Wales
Outlook for Future Growth
  Investigations into price fixing
    Department of Health
    Ranbaxy and Merck settle DOH claims
    Serious Fraud Office
Overview of the Domestic Industry
  Total Turnover
  UK Turnover
  Operating Profit
  Net Profit
  Employees
  Sales per Employee
Leading Players in the Market
  Actavis UK Ltd
    Actavis worldwide
    Actavis in the UK
    Products on the UK market
  Financial indicators
  Arrow Generics Ltd
    Products on the UK market
    Financial indicators
  Bristol Laboratories
    Products on the UK Market
    Financial indicators
  Crescent Pharma
    Products on the UK market
    Financial indicators
  Dr Reddy's Laboratories (UK) Ltd
    Dr Reddy's worldwide
    UK operations
    Financial indicators
  Focus Pharmaceuticals
    Products in the UK
    Financial Indicators
  Generics (UK) Ltd
    Merck Generics worldwide
    UK Operations
    Products in the UK market
    Financial indicators
  Genus Pharmaceuticals
    Products
    Financial indicators
  Goldshield Pharmaceuticals Ltd
    Goldshield Group
    Products
    Financial indicators
  Kent Pharmaceuticals
    Products
    Financial indicators
  Perrigo UK Ltd
    Products
    Financial indicators
  Pliva Pharma Ltd
    Pliva worldwide
    Pliva in the UK
    Financial indicators
  Ranbaxy (UK) Ltd
    Ranbaxy worldwide
    Ranbaxy in the UK
  Financial indicators
  Ratiopharm UK
    ratiopharm worldwide
    ratiopharm in the UK
    Financial indicators
  Rosemont Pharmaceuticals
    Products
    Financial indicators
  Sandoz
    Sandoz worldwide
    Sandoz in the UK
    Products
    Financial indicators
  Teva UK
  Teva worldwide
    Teva in the UK
    Financial indicators
  Winthrop Pharmaceuticals
    Winthrop worldwide
    Winthrop in the UK
    Products
    Financial indicators
  Wockhardt UK Ltd
    Wockhardt worldwide
    Wockhardt in the UK
    Products
    Financial indicators
Marketing Authorisations in 2006
Trading Companies
Wholesaling
  AAH Pharmaceuticals Ltd
  Alliance Boots (formerly Alliance Unichem)
    Exclusive Distribution Deal with Pfizer
  Mawdsleys
  Phoenix Healthcare Distribution Ltd
Retailing
  Major Pharmacy Chains
    Alliance Boots
    Lloyds Pharmacy
    Superdrug

APPENDIX 1: ANALYSIS OF LEADING PATENT-EXPIRED DRUGS

Amisulpride
Risperidone
Ramipril
Glimepiride
Ondansetron
Sumatriptan
Amlodipine
Citalopram
Fluconazole
Gabapentin
Lamotrigine
Meloxicam
Meloxicam
Sertraline
Tamsulosin
Terbinafine

APPENDIX 2: RISING USE OF GENERICS IN THE UK STATINS MARKET

Market Developments
Atorvastatin
Fluvastatin
Pravastatin
Rosuvastatin
Simvastatin

APPENDIX 3: GENERICS IN THE UK PPI MARKET

Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Rabeprazole sodium

APPENDIX 4: SOURCES

Espicom Sources
UK Government Sources
Industry Sources

APPENDIX 5: DIRECTORY

Regulators
Trade Bodies
Manufacturers
Skip to top


Emerging Generic Drug Markets in Europe US$ 1,390.00 Dec, 2007 · 196 pages
Generic Drugs: World Market 2013-2023 US$ 2,400.00 Nov, 2012 · 149 pages
Booming US Generic Drug Market US$ 1,000.00 Oct, 2010 · 50 pages
Generic Drug Market in Canada US$ 1,000.00 Nov, 2011 · 65 pages

Ask Your Question

Opportunities and Challenges for Generic Drugs in the UK 2007
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: